- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Veliparib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 153
- States / cities
- Phoenix, Arizona • Concord, California • La Jolla, California + 114 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- BRCA1 Mutation, BRCA2 Mutation
- Interventions
- Family Letter (Standard of Care), Educational Video, Mailed Saliva Kit for Genetic Testing, Telephone Counseling
- Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 524 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- New York, New York • Durham, North Carolina • Houston, Texas
- Conditions
- Ovarian Carcinoma
- Interventions
- Denosumab, Salpingo-Oophorectomy
- Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Ovarian Carcinoma
- Interventions
- Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
- Procedure · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 35 Years to 50 Years · Female only
- Enrollment
- 1,956 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2047
- U.S. locations
- 564
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more
- Conditions
- Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Interventions
- Diagnostic Laboratory Biomarker Analysis, Gemcitabine Hydrochloride, Pharmacological Study, Veliparib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 4
- States / cities
- Hershey, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
- Interventions
- metformin hydrochloride, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 25 Years to 55 Years · Female only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 27
- States / cities
- Duarte, California • Los Angeles, California • South Pasadena, California + 18 more
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Interventions
- soy isoflavones, placebo, questionnaire administration, magnetic resonance imaging, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, mammography
- Dietary Supplement · Other · Procedure
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 30 Years to 75 Years · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
- Interventions
- 3.0-T MRI, biopsy
- Device · Procedure
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
- Interventions
- Mifepristone 200 MG, Prophylactic mastectomy
- Drug · Procedure
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Carmel, Indiana • Indianapolis, Indiana
- Conditions
- BRCA1 Mutation, Breast Cancer
- Interventions
- recombinant human chorionic gonadotropin, microarray analysis, immunohistochemistry staining method, laboratory biomarker analysis, needle biopsy
- Biological · Genetic · Other + 1 more
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 20 Years to 40 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania